Cargando…
Interferon-α Treatment for Growing Teratoma Syndrome of the Testis
A 23-year-old man with a right scrotal mass and back pain was referred for further treatment after right radical orchiectomy for testicular cancer. CT scans brought by the patient showed extensive metastasis to the retroperitoneal lymph nodes with no lung involvement. α-Fetoprotein and human chorion...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636960/ https://www.ncbi.nlm.nih.gov/pubmed/23626597 http://dx.doi.org/10.1159/000350897 |
_version_ | 1782267385443516416 |
---|---|
author | Inoue, Masahiro Hisasue, Shin-ichi Nagae, Mika China, Toshiyuki Saito, Keisuke Isotani, Shuji Yamaguchi, Raizo Ide, Hisamitsu Muto, Satoru Horie, Shigeo |
author_facet | Inoue, Masahiro Hisasue, Shin-ichi Nagae, Mika China, Toshiyuki Saito, Keisuke Isotani, Shuji Yamaguchi, Raizo Ide, Hisamitsu Muto, Satoru Horie, Shigeo |
author_sort | Inoue, Masahiro |
collection | PubMed |
description | A 23-year-old man with a right scrotal mass and back pain was referred for further treatment after right radical orchiectomy for testicular cancer. CT scans brought by the patient showed extensive metastasis to the retroperitoneal lymph nodes with no lung involvement. α-Fetoprotein and human chorionic gonadotropin were elevated preoperatively (384 ng/ml and 112 mIU/ml, respectively). Confirmation of the histopathologic examination revealed a mixed germ cell tumor (95% immature teratoma and 5% embryonal carcinoma). We started the patient on chemotherapy with bleomycin, etoposide, and cisplatin (BEP). After a single course, tumor markers began to normalize, but there was radiologic evidence of continued growth of the retroperitoneal mass and new metastases in the lung. The patient was given 2 courses of salvage chemotherapy with etoposide, ifosfamide, and cisplatin (VIP). However, the mass and lung metastases continued to progress, and the patient was growing rapidly intolerant of the side effects of treatment (i.e., nausea, appetite loss, and pancytopenia). After thorough discussion with the patient and his family, we decided to start the patient on interferon (IFN)-α therapy. Natural, nonrecombinant IFN-α (OIF, Otsuka, Japan) 5,000,000 IU was administered twice weekly with approval of the ethics committee of our institution. The patient responded moderately with marked deceleration of tumor growth and stabilization of the lung metastases. He is alive and well at 16 months on IFN-α therapy. |
format | Online Article Text |
id | pubmed-3636960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-36369602013-04-26 Interferon-α Treatment for Growing Teratoma Syndrome of the Testis Inoue, Masahiro Hisasue, Shin-ichi Nagae, Mika China, Toshiyuki Saito, Keisuke Isotani, Shuji Yamaguchi, Raizo Ide, Hisamitsu Muto, Satoru Horie, Shigeo Case Rep Nephrol Urol Published online: April, 2013 A 23-year-old man with a right scrotal mass and back pain was referred for further treatment after right radical orchiectomy for testicular cancer. CT scans brought by the patient showed extensive metastasis to the retroperitoneal lymph nodes with no lung involvement. α-Fetoprotein and human chorionic gonadotropin were elevated preoperatively (384 ng/ml and 112 mIU/ml, respectively). Confirmation of the histopathologic examination revealed a mixed germ cell tumor (95% immature teratoma and 5% embryonal carcinoma). We started the patient on chemotherapy with bleomycin, etoposide, and cisplatin (BEP). After a single course, tumor markers began to normalize, but there was radiologic evidence of continued growth of the retroperitoneal mass and new metastases in the lung. The patient was given 2 courses of salvage chemotherapy with etoposide, ifosfamide, and cisplatin (VIP). However, the mass and lung metastases continued to progress, and the patient was growing rapidly intolerant of the side effects of treatment (i.e., nausea, appetite loss, and pancytopenia). After thorough discussion with the patient and his family, we decided to start the patient on interferon (IFN)-α therapy. Natural, nonrecombinant IFN-α (OIF, Otsuka, Japan) 5,000,000 IU was administered twice weekly with approval of the ethics committee of our institution. The patient responded moderately with marked deceleration of tumor growth and stabilization of the lung metastases. He is alive and well at 16 months on IFN-α therapy. S. Karger AG 2013-04-10 /pmc/articles/PMC3636960/ /pubmed/23626597 http://dx.doi.org/10.1159/000350897 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published online: April, 2013 Inoue, Masahiro Hisasue, Shin-ichi Nagae, Mika China, Toshiyuki Saito, Keisuke Isotani, Shuji Yamaguchi, Raizo Ide, Hisamitsu Muto, Satoru Horie, Shigeo Interferon-α Treatment for Growing Teratoma Syndrome of the Testis |
title | Interferon-α Treatment for Growing Teratoma Syndrome of the Testis |
title_full | Interferon-α Treatment for Growing Teratoma Syndrome of the Testis |
title_fullStr | Interferon-α Treatment for Growing Teratoma Syndrome of the Testis |
title_full_unstemmed | Interferon-α Treatment for Growing Teratoma Syndrome of the Testis |
title_short | Interferon-α Treatment for Growing Teratoma Syndrome of the Testis |
title_sort | interferon-α treatment for growing teratoma syndrome of the testis |
topic | Published online: April, 2013 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636960/ https://www.ncbi.nlm.nih.gov/pubmed/23626597 http://dx.doi.org/10.1159/000350897 |
work_keys_str_mv | AT inouemasahiro interferonatreatmentforgrowingteratomasyndromeofthetestis AT hisasueshinichi interferonatreatmentforgrowingteratomasyndromeofthetestis AT nagaemika interferonatreatmentforgrowingteratomasyndromeofthetestis AT chinatoshiyuki interferonatreatmentforgrowingteratomasyndromeofthetestis AT saitokeisuke interferonatreatmentforgrowingteratomasyndromeofthetestis AT isotanishuji interferonatreatmentforgrowingteratomasyndromeofthetestis AT yamaguchiraizo interferonatreatmentforgrowingteratomasyndromeofthetestis AT idehisamitsu interferonatreatmentforgrowingteratomasyndromeofthetestis AT mutosatoru interferonatreatmentforgrowingteratomasyndromeofthetestis AT horieshigeo interferonatreatmentforgrowingteratomasyndromeofthetestis |